StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Xeris Biopharma's EV/EBITDA was 79.1× on Nov 11, 2026, against 119.1× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202679.1×−50.0
2025Dec 31, 2025129.1×–

More Xeris Biopharma figures

See a number that looks wrong?